Showing results (21-30 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|June 14, 2013
Antitumor activity of semisynthetic derivatives of Aconitum alkaloidsAinura Chodoeva, Jean-Jacques Bosc, Lydia Lartigue, et al.
Investigational New Drugs|September 4, 2015
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumorsSuzanne F Jones, Lillian L Siu, Johanna C Bendell, et al.
Investigational New Drugs|September 4, 2015
Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinibYuzo Yamamoto, Isamu Okamoto, Kohei Otsubo, et al.
Investigational New Drugs|January 16, 2016
Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignanciesEmiliano Calvo, Guru Reddy, Valentina Boni, et al.
Investigational New Drugs|December 22, 2015
Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulinLee-Chuan C Yeh, Asok Banerjee, Veena Prasad, et al.
Investigational New Drugs|January 22, 2016
A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignanciesGeert A Cirkel, Bojana Milojkovic Kerklaan, Frédéric Vanhoutte, et al.
Investigational New Drugs|February 12, 2016
Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3-1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjectsC E Halstenson, T Shamp, M A Gargano, et al.
Investigational New Drugs|February 5, 2016
RRx-001, A novel dinitroazetidine radiosensitizerBryan Oronsky, Jan Scicinski, Shoucheng Ning, et al.
Investigational New Drugs|May 27, 2016
A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancerPaul L Swiecicki, Emily Bellile, Assuntina G Sacco, et al.
Investigational New Drugs|April 4, 2016
Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance studyNeeraj Gupta, Richard Labotka, Guohui Liu, et al.
Pageof 372